Skip to content

American Journal of Psychiatry

ISSN 0002-953X, 1535-7228

132 papers in the library · 19,379 citations · publishing 1948-2026

Papers

Sort Most recent Most cited

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists

American Journal of Psychiatry October 9, 2024 Caesar G. Imperio, Frances R. Levin, Diana Martínez 9 citations

Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreated, and there is a need for psychiatrists, of all specialties, to address this pervasive clinical problem. In this review, the authors' goal is to provide a resource that describes treatments for SUD, using neuroscience as a framework. They discuss...

Entactogen Effects of Ketamine: A Reverse-Translational Study.

American Journal of Psychiatry September 1, 2024 Evan M. Hess, Dede Greenstein, Olivia L Hutchinson et al. 12 citations

The authors sought to assess the prosocial, entactogen effects of ketamine. Pleasure from social situations was assessed in a sample of participants with treatment-resistant depression from randomized, double-blind, placebo-controlled studies, using four items of the Snaith-Hamilton Pleasure Scale (SHAPS) at five time points over 1 week following treatment with ketamine (0.5 mg/kg...

DOI: 10.1176/appi.ajp.20230980 (opens in new tab) Full text (opens in new tab) Depressive disorders Entactogens Ketamine/esketamine #ketamine ketamine therapy +6

Mindfulness-Oriented Recovery Enhancement for Veterans and Military Personnel on Long-Term Opioid Therapy for Chronic Pain: A Randomized Clinical Trial

American Journal of Psychiatry January 10, 2024 Eric L Garland, Yoshio Nakamura, Craig J. Bryan et al.

OBJECTIVE. Evaluate the efficacy of Mindfulness-Oriented Recovery Enhancement (MORE) for past and current military personnel prescribed long-term opioid therapy (LTOT) for chronic pain. METHODS. In a clinical trial, 230 past and current U.S. military personnel prescribed LTOT were randomized (1:1) to MORE or supportive psychotherapy (in-person and then online via Zoom after onset of COVID-19)....

Overview of Alcohol Use Disorder.

American Journal of Psychiatry August 1, 2023 Henry R. Kranzler 92 citations

Alcohol is regularly consumed throughout most of the world, including by nearly half the U.S. population age 12 or older. Heavy drinking, which is also common, contributes to multiple adverse medical, psychiatric, and social outcomes and more than 140,000 deaths annually in the United States. It is the major risk factor for alcohol use disorder (AUD), whose current U.S. prevalence is 11%....

Psychedelics as Transformative Therapeutics.

American Journal of Psychiatry May 1, 2023 Bryan L. Roth, Ryan H. Gumpper 55 citations

Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most of the basic science has utilized these compounds as probes to interrogate various endogenous neurotransmitter systems-mainly the serotonin 5-HT2A receptor. With the renewed interest in utilizing these compounds...

DOI: 10.1176/appi.ajp.20230172 (opens in new tab) Full text (opens in new tab) Hallucinogenic drugs Pharmacokinetics Psychedelics Psychopharmacology

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial

American Journal of Psychiatry September 21, 2022 Rebecca B Price, Crystal Spotts, Benjamin Panny et al.

Background: Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. We tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response. Methods: 154 adults (age 18–60) with unipolar, treatment-resistant depression were...

Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial

American Journal of Psychiatry July 28, 2022 Joseph Wielgosz, Tammi R. A. Kral, David M Perlman et al. 21 citations

OBJECTIVE: Mindfulness-based interventions are widely used to target pain, yet their neural mechanisms of action are insufficiently understood. The authors studied neural and subjective pain response in a randomized active-control trial of mindfulness-based stress reduction (MBSR) alongside long-term meditation practitioners. METHODS: Healthy participants (N=115) underwent functional...

DOI: 10.1176/appi.ajp.21020145 (opens in new tab) Full text (opens in new tab) Meditation Mindfulness-based stress reduction Randomized controlled trial Neuroimaging +3

Persistent Dissociation and its Neural Correlates Uniquely Predict Worse Outcomes after Trauma Exposure

American Journal of Psychiatry June 22, 2022 Lauren A M Lebois, N. Harnett, S. V. van Rooij et al.

Objective: Dissociation, a disruption or discontinuity in psychological functioning, is often linked with worse psychiatric symptoms; however, the prognostic value of dissociation after trauma is inconsistent. Determining whether trauma-related dissociation is uniquely predictive of later outcomes would enable early identification of at-risk trauma populations. We completed the largest...

Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.

American Journal of Psychiatry May 18, 2022 Herriot Tabuteau, A. Jones, Ashley Anderson et al.

OBJECTIVE Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major...

Risks and Benefits of Cannabis and Cannabinoids in Psychiatry.

American Journal of Psychiatry February 2022 Kevin P Hill, Mark S. Gold, Charles B. Nemeroff et al.

The United States is in the midst of rapidly changing laws regarding cannabis. The increasing availability of cannabis for recreational and medical use requires that mental health clinicians be knowledgeable about evidence to be considered when counseling both patients and colleagues. In this review, the authors outline the evidence from randomized double-blind placebo-controlled trials for...

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.

American Journal of Psychiatry December 22, 2021 Maurizio Fava, S. Stahl, Luca Pani et al.

OBJECTIVE The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. METHODS A 7-day phase 2 multicenter randomized double-blind placebo-controlled...

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

American Journal of Psychiatry March 17, 2021 Roger S McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff et al. 694 citations

Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to achieve full syndromal and functional recovery with the index and subsequent pharmacological treatments. Ketamine and esketamine represent...

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.

American Journal of Psychiatry March 3, 2021 J. Dwyer, Angeli Landeros‐Weisenberger, Jessica A. Johnson et al. 163 citations

OBJECTIVE Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown. The authors conducted an active-placebo-controlled study of ketamine's safety and efficacy in adolescents. METHODS In this proof-of-concept randomized,...

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.

American Journal of Psychiatry January 5, 2021 Adriana Feder, Sara Costi, Sarah B. Rutter et al. 239 citations

OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first...

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.

American Journal of Psychiatry December 2, 2019 Elias Dakwar, Frances R. Levin, C. Hart et al. 179 citations

OBJECTIVE Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motivational enhancement therapy affects drinking outcomes....

A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.

American Journal of Psychiatry June 24, 2019 Elias Dakwar, E. Nunes, C. Hart et al. 179 citations

OBJECTIVE Research has suggested that subanesthetic doses of ketamine may work to improve cocaine-related vulnerabilities and facilitate efforts at behavioral modification. The purpose of this trial was to test whether a single ketamine infusion improved treatment outcomes in cocaine-dependent adults engaged in mindfulness-based relapse prevention. METHODS Fifty-five cocaine-dependent...

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

American Journal of Psychiatry May 21, 2019 Vanina Popova, Ella Daly, Madhukar H. Trivedi et al. 879 citations

OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active...

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.

American Journal of Psychiatry March 29, 2019 J. Phillips, S. Norris, Jeanne Talbot et al. 416 citations

OBJECTIVE Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response with maintenance...

Smoking Cannabis and Acquired Impairments in Cognition: Starting Early Seems Like a Really Bad Idea.

American Journal of Psychiatry February 1, 2019 Philip D. Harvey

Societal attitudes toward cannabis use are changing rapidly. In the past decade, there has been awide-ranging movement toward removal of criminal sanctions on cannabis use, and in some localities cannabis use is permitted in a regulated manner, similar to alcohol. This movement has raised some concerns about whether we understand the full implications of cannabis use, particularly in younger...

Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine

American Journal of Psychiatry January 4, 2019 Satoshi Deyama, Eunyoung Bang, Eric S. Wohleb et al. 100 citations

OBJECTIVE: -methyl-d-aspartate receptor antagonist ketamine produces rapid and sustained antidepressant actions even in patients with treatment-resistant depression. Vascular endothelial growth factor (VEGF) has been implicated in the effects of conventional monoamine-based antidepressants, but the role of VEGF in the rapid antidepressant actions of ketamine remains unclear. The authors...

DOI: 10.1176/appi.ajp.2018.17121368 (opens in new tab) Ketamine Antidepressant Prefrontal cortex Neurotrophic factors +5

A Population-Based Analysis of the Relationship Between Substance Use and Adolescent Cognitive Development.

American Journal of Psychiatry October 3, 2018 Jean-François G Morin, Mohammad H Afzali, Josiane Bourque et al.

Objective: Alcohol and cannabis misuse are related to impaired cognition. When inferring causality, four nonexclusive theoretical models can account for this association: 1) a common underlying vulnerability model; 2) a neuroplasticity model in which impairment is concurrent with changes in substance use but temporary because of neuroplastic brain processes that restore function; 3) a...

Individual Treatment of Posttraumatic Stress Disorder Using Mantram Repetition: A Randomized Clinical Trial.

American Journal of Psychiatry October 1, 2018 Jill E Bormann, Steven R Thorp, Eric Smith et al.

Previous studies suggest that group "mantram" (sacred word) repetition therapy, a non-trauma-focused complementary therapy for posttraumatic stress disorder (PTSD), may be an effective treatment for veterans. The authors compared individually delivered mantram repetition therapy and another non-trauma-focused treatment for PTSD. The study was a two-site, open-allocation, blinded-assessment...

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

American Journal of Psychiatry August 29, 2018 Nolan Williams, Boris D. Heifets, Christine Blasey et al. 510 citations

OBJECTIVE: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation. The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects. METHOD: In a proposed double-blind crossover study of 30 adults with treatment-resistant...

DOI: 10.1176/appi.ajp.2018.18020138 (opens in new tab) Ketamine Antagonism Antidepressant Pharmacology +2

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

American Journal of Psychiatry April 16, 2018 Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin et al. 666 citations

OBJECTIVE: The authors compared the efficacy of standard-of-care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among individuals at imminent suicide risk. METHOD: In a double-blind, multicenter, proof-of-concept study, 68 participants were randomly assigned to receive esketamine (84 mg) or placebo twice weekly for 4...